---
title: 今年美国生物制药领域最火热的两个新靶点药无疑是GLP-1激动剂和beta-amyloid拮抗剂，后者用于治疗AD（阿尔兹海默症），即老年痴呆症的一种。今年Biogen的Leqembi...
date: '2023-07-29'
linkTitle: https://weibo.com/1251560221/Nc4WKvOYn
source: 子陵在听歌的微博
description: 今年美国生物制药领域最火热的两个新靶点药无疑是GLP-1激动剂和beta-amyloid拮抗剂，后者用于治疗AD（阿尔兹海默症），即老年痴呆症的一种。今年Biogen的Leqembi获得了FDA的批准。Leqembi虽然不能治愈或逆转AD，但是可以将该疾病进展缓解几个月。<br><br>Biogen
  CEO Chris Viehbacher在接受STAT采访对于Leqembi和AD药物开发做了个比喻特别好，他说：“People have been throwing
  things at castle walls for decades, trying to make any dent, this is first time
  we put a chunk in the wall.” <br><br>这让我想起了HIV治愈研究，过去十年其实HIV领域就是throwing things
  at castle walls try to make a ...
disable_comments: true
---
今年美国生物制药领域最火热的两个新靶点药无疑是GLP-1激动剂和beta-amyloid拮抗剂，后者用于治疗AD（阿尔兹海默症），即老年痴呆症的一种。今年Biogen的Leqembi获得了FDA的批准。Leqembi虽然不能治愈或逆转AD，但是可以将该疾病进展缓解几个月。<br><br>Biogen CEO Chris Viehbacher在接受STAT采访对于Leqembi和AD药物开发做了个比喻特别好，他说：“People have been throwing things at castle walls for decades, trying to make any dent, this is first time we put a chunk in the wall.” <br><br>这让我想起了HIV治愈研究，过去十年其实HIV领域就是throwing things at castle walls try to make a ...